First Patient Enrolled in Ph 1b FORTRESS Trial of NG-350A in Locally Advanced Rectal Cancer Patients April 15, 2025
FDA Approves Opdivo + Yervoy as a Treatment for Patients with 1L MSI-H or dMMR Unresectable or Metastatic CRC April 15, 2025
FDA Clears IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic CRC March 18, 2025
FDA accepts Supplemental BLA for Opdivo + Yervoy for Patients with Unresectable or Metastatic MSI-H or MRD CRC March 4, 2025
Investigator Initiated Ph 2 Trial for Neoadjuvant Muzastotug (ADG126) in CRC Announced February 28, 2025
Progress and Expansion of Clinical Collaboration Program for ADG126 (muzastotug) + KEYTRUDA combo in MSS CRC announced February 10, 2025
BRAFTOVI Combination Regimen Significantly Improved PFS and OS in Ph 3 BREAKWATER Trial February 5, 2025
Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study of sirexatamab (DKN-01) Reported February 4, 2025
ASCO GI 2025: Encouraging Results from Ph 1b/2 STELLAR-001 Trial of Zanzalintinib +/- Immune Checkpoint Inhibitor in Metastatic CRC announced January 28, 2025
ASCO GI 2025: Results from CheckMate -8HW Analysis of Opdivo + Yervoy Compared to Opdivo Monotherapy in Patients with MSI-H or MMRD Metastatic CRC announced January 28, 2025
ASCO GI 2025: Initial Ph 2 Data for Vilastobart (XTX101) in Combination with Atezolizumab in Patients with MSS CRC announced January 28, 2025
ASCO GI 2025: Results from Ph 3 CALGB (Alliance) / SWOG 80702 Clinical Trial in CRC announced January 28, 2025
ASCO GI 2025: BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic CRC from the Ph 3 BREAKWATER trial January 28, 2025
FDA Approves Lumakras® (Sotorasib) + Vectibix® (Panitumumab) For Chemorefractory KRAS G12C-Mutated Metastatic CRC January 21, 2025
Invikafusp Alfa (STAR0602) Receives US FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic TMB-H CRC January 15, 2025
EC approves Opdivo + Yervoy for the 1L Treatment of Adult Patients with MSI-H or dMMR Metastatic CRC December 31, 2024
U.S. FDA Approves BRAFTOVI Combination Regimen as 1L Treatment of BRAF V600E-Mutant mCRC December 25, 2024
Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer December 18, 2024
Positive Initial Data from First-line RAS-mutated mCRC Ph 2 CRDF-004 trial evaluating onvansertib + SoC Announced December 18, 2024
FDA Clears IND Application for Ph 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic CRC December 4, 2024
Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology November 26, 2024
Positive CHMP Opinion for Opdivo® (nivolumab) + Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with MSI-H or MRD Metastatic CRC November 19, 2024
